S Belo1,2,3, A C Santos4,5, A Madureira6,7,8, J Pereira9, A Sarmento10,11,12, D Carvalho13,14,15, P Freitas16,17,18. 1. Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar de São João, Alameda Prof. Hernani Monteiro, Porto, 4200, Portugal. sandra.belo@gmail.com. 2. Faculty of Medicine, University of Porto, Porto, Portugal. sandra.belo@gmail.com. 3. Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal. sandra.belo@gmail.com. 4. Faculty of Medicine, University of Porto, Porto, Portugal. acsantos@medup.pt. 5. Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal. acsantos@medup.pt. 6. Faculty of Medicine, University of Porto, Porto, Portugal. ajbmadureira@gmail.com. 7. Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal. ajbmadureira@gmail.com. 8. Department of Radiology, Centro Hospitalar de São João, Porto, Portugal. ajbmadureira@gmail.com. 9. Department of Nuclear Medicine, Centro Hospitalar de São João, Porto, Portugal. jorgepgpereira@gmail.com. 10. Faculty of Medicine, University of Porto, Porto, Portugal. antonio.sarmento@hsjoao.min-saude.pt. 11. Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal. antonio.sarmento@hsjoao.min-saude.pt. 12. Department of Infectious Diseases, Centro Hospitalar de São João, Porto, Portugal. antonio.sarmento@hsjoao.min-saude.pt. 13. Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar de São João, Alameda Prof. Hernani Monteiro, Porto, 4200, Portugal. davidecarvalho@gmail.com. 14. Faculty of Medicine, University of Porto, Porto, Portugal. davidecarvalho@gmail.com. 15. Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal. davidecarvalho@gmail.com. 16. Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar de São João, Alameda Prof. Hernani Monteiro, Porto, 4200, Portugal. paula_freitas@sapo.pt. 17. Faculty of Medicine, University of Porto, Porto, Portugal. paula_freitas@sapo.pt. 18. Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal. paula_freitas@sapo.pt.
Abstract
PURPOSE: Combined antiretroviral therapy (cART) for the treatment of HIV-1 infection has been associated with complications, including lipodystrophy. Several interleukins have been implicated in the pathology and physiology of lipodystrophy. The present study aimed to compare the levels of IL-4 and IL-6 in HIV-1 patients under cART with and without, clinically and fat mass ratio defined, lipodystrophy and in four different groups of fat distribution: (1) no lipodystrophy; (2) isolated central fat accumulation; (3) isolated lipoatrophy and (4) mixed forms of lipodystrophy. METHODS: In the present cross-sectional study we evaluated IL-4 and IL-6 levels, insulin resistance and insulin sensitivity indexes in 86 HIV-infected adults under cART. RESULTS: No significant differences in IL-4 and IL-6 levels between the four groups of body composition were observed. Patients with HOMA-IR >4 presented higher levels of IL-6 and lower levels of IL-4, although without statistical significance. No correlation between IL-6, or IL-4, HOMA-IR and quantitative body fat mass distribution was found. CONCLUSION: Although there was a tendency for patients with isolated lipoatrophy and isolated fat accumulation to present higher IL-6 levels, these differences were not statistically significant. No differences were found relating IL-4 levels.
PURPOSE: Combined antiretroviral therapy (cART) for the treatment of HIV-1 infection has been associated with complications, including lipodystrophy. Several interleukins have been implicated in the pathology and physiology of lipodystrophy. The present study aimed to compare the levels of IL-4 and IL-6 in HIV-1patients under cART with and without, clinically and fat mass ratio defined, lipodystrophy and in four different groups of fat distribution: (1) no lipodystrophy; (2) isolated central fat accumulation; (3) isolated lipoatrophy and (4) mixed forms of lipodystrophy. METHODS: In the present cross-sectional study we evaluated IL-4 and IL-6 levels, insulin resistance and insulin sensitivity indexes in 86 HIV-infected adults under cART. RESULTS: No significant differences in IL-4 and IL-6 levels between the four groups of body composition were observed. Patients with HOMA-IR >4 presented higher levels of IL-6 and lower levels of IL-4, although without statistical significance. No correlation between IL-6, or IL-4, HOMA-IR and quantitative body fat mass distribution was found. CONCLUSION: Although there was a tendency for patients with isolated lipoatrophy and isolated fat accumulation to present higher IL-6 levels, these differences were not statistically significant. No differences were found relating IL-4 levels.
Authors: I Presta; F Andreozzi; E Succurro; M A Marini; E Laratta; R Lauro; M L Hribal; F Perticone; G Sesti Journal: Nutr Metab Cardiovasc Dis Date: 2009-01-26 Impact factor: 4.222
Authors: Katja Kannisto; Jussi Sutinen; Elena Korsheninnikova; Rachel M Fisher; Ewa Ehrenborg; Karl Gertow; Antti Virkamäki; Tuulikki Nyman; Hubert Vidal; Anders Hamsten; Hannele Yki-Järvinen Journal: AIDS Date: 2003-08-15 Impact factor: 4.177
Authors: E Bonnet; C Delpierre; A Sommet; F Marion-Latard; R Hervé; C Aquilina; E Labau; M Obadia; B Marchou; P Massip; B Perret; J Bernard Journal: J Clin Densitom Date: 2005 Impact factor: 2.963